A Phase 2 interventional study of Lodotra and Cortancyl in Asthma, sponsored by Amgen. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing prednisone in Asthma — 2 open to participants now, 2 under way, none of them phase 3. Prednisone · Asthma.
Among the 11 studies testing prednisone in Asthma, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is the only one in phase 2, and was the 4th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →2 of the 11 studies testing prednisone in Asthma are open now, in 1 country. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+
Andréanne Côté
Ages 18+
By country, each count listing its studies:
Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 40 across the 11 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
13 studies in Asthma by Amgen: none open now, 2 under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 13 studies in Asthma by Amgen, this one is the 11th largest by enrollment, is the only one that started in 2008, is one of 6 in phase 2, and was the 2nd registered.
Amgen’s Asthma studies by the year they started, since 2007.
1 of the studies testing prednisone in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07228052Montefiore Medical CenterGiving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing prednisone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 13 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms.
Study with completed results acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Poorly controlled asthma, defined as meeting at least one of the following within the 4 weeks prior to Visit V0:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
Drug: Lodotra
During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
Drug: Cortancyl
Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
Also known as: modified release tablet formulation of prednisone
Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
Also known as: immediate release prednisone tablets
Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment
Variation in the total number of nocturnal awakenings during the last 2 weeks of run-in treatment with Cortancyl and the last 2 weeks of treatment with Lodotra.
Time frame: 4 weeks and 8 weeks
Asthmatic patients, aged at least 18 years, suffering from severe persistent asthma, having nocturnal symptoms and receiving treatment with oral glucocorticoids were recruited from Hôpital Bichat between July 2008 and March 2010.
| Milestone | Safety Population |
|---|---|
| Started | 12 |
| Completed | 7 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Asthma exacerbation | 1 |
| Withdrew: Violation of inclusion/exclusion criteri | 3 |
| Milestone | Safety Population |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
Variation in the total number of nocturnal awakenings during the last 2 weeks of run-in treatment with Cortancyl and the last 2 weeks of treatment with Lodotra.
| number of nocturnal awakenings | Lodotra | Cortancyl |
|---|---|---|
| Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment | 2.1 ± 4.41 | 10.0 ± 5.45 |
Collected over Adverse event data were collected from the time the patient gave informed consent until the end of the follow-up visit or 30 days after last study drug administration, whichever occurred later.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lodotra | — | 0/7 (0%) | 6/7 (85.7%) |
| Cortancyl | — | 1/12 (8.3%) | 7/12 (58.3%) |
| Event | Lodotra | Cortancyl |
|---|---|---|
| asthmaRespiratory, thoracic and mediastinal disorders | 0/7 | 1/12 |
| arterial thrombosisVascular disorders | 0/7 | 1/12 |
| Event | Lodotra | Cortancyl |
|---|---|---|
| asthmaRespiratory, thoracic and mediastinal disorders | 2/7 | 2/12 |
| insomniaPsychiatric disorders | 2/7 | 0/12 |
| bronchitisInfections and infestations | 0/7 | 3/12 |
| arthralgiaMusculoskeletal and connective tissue disorders | 1/7 | 0/12 |
| coughRespiratory, thoracic and mediastinal disorders | 1/7 | 0/12 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 1/7 | 0/12 |
| hernial eventrationGastrointestinal disorders | 1/7 | 0/12 |
| influenza like illnessGeneral disorders | 1/7 | 1/12 |
| menstrual disorderReproductive system and breast disorders | 1/7 | 0/12 |
| oedemaGeneral disorders | 1/7 | 0/12 |
| Age, Categorical(Participants) | Safety Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 11 |
| >=65 years | 1 |
| Age, Continuous(years) | Safety Population |
|---|---|
| Mean | 48.9 ± 14.40 |
| Sex: Female, Male(Participants) | Safety Population |
|---|---|
| Female | 11 |
| Male | 1 |
| Region of Enrollment(participants) | Safety Population |
|---|---|
| France | 12 |
The record gives a start of Jun 2008, a primary completion of Mar 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisone